sentence: 51 The clinical application of NOX-A12 has shown synergistic effects for combinatorial treatment with standard therapy in relapsed or refractory multiple myeloma and chronic lymphatic leukemia.31 37 The potential of NOX-A12 to treat glioblastoma in combination with radiotherapy is currently being investigated ( clinical trial identifier NCT04121455 ) .52 The OPERA trial is the first clinical trial utilizing the spiegelmer technology to inhibit selectively the chemokine CXCL12 in patients with colorectal or pancreatic cancer.Last year , two clinical trials investigated the effect of targeting CXCR4 ( one of the two receptors of CXCL12 ) using two independent drugs in patients with metastatic pancreatic or CRC.32 33 In the COMBAT trial , the treatment regimen was different from the current study , but also started with a phase of monotherapy followed by combination with immune checkpoint blockade .